Updates are available Correction dated 2025-05-20
Click to view Correction: https://doi.org/10.1007/s12185-025-04012-1
-
Authors
Kim, Kihyun
Verburgh, Estelle
Mitina, Tatiana
Chen, Wenming
Yeh, Su-Peng
Schutz, Natalia
Alsharif, Fahad
Chng, Wee Joo
Huang, Zhongwen
Beksac, Meral
-
Funding
Funding for this research was provided by:
Takeda Pharmaceuticals
- License Information
-
More Information
Article History
Received: 1 September 2024
Revised: 11 March 2025
Accepted: 11 March 2025
First Online: 15 April 2025
Change Date: 22 May 2025
Change Type: Update
Change Details: The original online version of this article was revised for retrospective open access.
Change Date: 20 May 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s12185-025-04012-1
Declarations
:
: Kihyun Kim has received research funding from Janssen, BMS, and Amgen, and served as a consultant for Janssen, BMS, Amgen, Takeda, and LG Chem. Estelle Verburgh has received research funding from MSD and Takeda, received honoraria and speaker’s bureau from Takeda, served in an advisory role for MSD, NovoNordisk, and Takeda, and has unpaid roles in the executive committees of South African Clinical Hematology Society and South African Stem Cell Transplantation Society. Tatiana Mitina has received honoraria and serves as a member on the Board of Directors or advisory committee for Takeda. Wenming Chen has received honoraria from Takeda, Johnson & Johnson, Beigene, Amgen, Sanofi, Antengene, and Novartis. Su-Peng Yeh has received honoraria from Abbvie, Amgen, Janssen, Astellas, Astra Zeneca, Novartis, Sanofi, Roche, Bristol Myers Squibb, and Takeda, and has served in an advisory role for Abbvie, Amgen, Janssen, Astellas, Astex, Novartis, Sanofi, and Takeda. Natalia Schutz has received honoraria, research funding, and serves on the advisory board for Takeda, Amgen, Johnson & Johnson, and Sanofi. Fahad Alsharif has no conflicts of interest. Wee Joo Chng has received honoraria from Takeda, Johnson & Johnson, BMS/Celgene, Amgen, Abbvie, Sanofi, Pfizer, Antengene, and Novartis, and research funding from Johnson & Johnson, BMS/Celgene, Novartis, and Aslan. Zhongwen Huang is an employee and shareholder of Takeda Pharmaceuticals. Meral Beksac has served on the advisory board and speakers bureau for Amgen, Janssen, Sanofi, and Takeda, and on the advisory board for Oncopeptides.
